Nasal Glucagon 1 mg + Nasal Glucagon 2 mg + SC Glucagon + Nasal Glucagon 3 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoglycemia
Conditions
Hypoglycemia
Trial Timeline
Mar 1, 2012 → Jul 1, 2012
NCT ID
NCT01556594About Nasal Glucagon 1 mg + Nasal Glucagon 2 mg + SC Glucagon + Nasal Glucagon 3 mg
Nasal Glucagon 1 mg + Nasal Glucagon 2 mg + SC Glucagon + Nasal Glucagon 3 mg is a phase 2 stage product being developed by Eli Lilly for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01556594. Target conditions include Hypoglycemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01556594 | Phase 2 | Completed |
Competing Products
20 competing products in Hypoglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 1416 (INN imapextide) | MBX Biosciences | Phase 2 | 47 |
| MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C) | MBX Biosciences | Phase 1 | 28 |
| Nasal Glucagon | Eli Lilly | Phase 3 | 77 |
| Glucagon + Insulin | Abvance Therapeutics | Phase 1 | 25 |
| Nasal Glucagon + Intramuscular Glucagon | Eli Lilly | Phase 1 | 33 |
| Nasal Glucagon | Eli Lilly | Phase 3 | 77 |
| Eplerenone + Placebo | Johnson & Johnson | Pre-clinical | 23 |
| Sitagliptin phosphate + Placebo | Merck | Approved | 85 |
| Pasireotide | Novartis | Phase 1 | 33 |
| Dasiglucagon | Novo Nordisk | Phase 3 | 76 |
| Glucagen + Mayne Glucagon | Pfizer | Phase 1 | 32 |
| Pramlintide | Bristol Myers Squibb | Approved | 84 |
| dasiglucagon + placebo + GlucaGen HypoKit | Zealand Pharma | Phase 3 | 74 |
| Dasiglucagon + Placebo | Zealand Pharma | Phase 1 | 30 |
| Dasiglucagon + Dasiglucagon + Placebo | Zealand Pharma | Phase 2 | 49 |
| ZP4207 + Glucagon | Zealand Pharma | Phase 1 | 30 |
| ZP4207 + Placebo | Zealand Pharma | Phase 1 | 30 |
| Dasiglucagon + Placebo | Zealand Pharma | Phase 3 | 74 |
| dasiglucagon + GlucaGen | Zealand Pharma | Phase 3 | 74 |
| Dasiglucagon + Placebo | Zealand Pharma | Phase 2 | 49 |